全身性強皮症における血小板の多面的な役割:止血を超えて!
Veronica Batani1,2,3, Aslıhan Avanoglu Guler4, Jelena Colic5,6
1Department of Medical and Surgical Sciences for children and adults, University Hospital of Modena and Reggio Emilia School of Medicine, Modena.
Current opinion in hematology
|March 2, 2026
まとめ
血小板は全身性強皮症(SSc)における炎症と凝固の主要な促進因子であり、臓器障害に寄与する。これらの血小板駆動経路を理解することは、SScの新しい治療法につながる可能性がある。
科学分野:
- 血液学
- 免疫学
- リウマチ学
背景:
- 全身性強皮症(SSc)は、血管損傷、免疫問題、線維症を伴う。
- 従来の危険因子を超えた、SScにおける説明不能な血栓症の負担が存在する。
- 血小板は、SScの病態生理における中心的な役割を担うことがますます認識されている。
研究 の 目的:
- SScにおける新たな血小板駆動メカニズムをレビューする。
- 止血を超えた血小板の役割を強調する。
- 臓器障害を伝播する血管内メッセンジャーとしての血小板について議論する。
主な方法:
- 実験的および臨床的証拠の文献レビュー。
- SScにおける血小板活性化および機能の分析。
- 免疫細胞との血小板相互作用の検討。
主要な成果:
- SScにおける血小板は、内皮損傷と炎症により持続的な活性化を示す。
- 活性化された血小板は、好中球との相互作用を通じて免疫血栓症を促進する。
- 血小板メディエーターは、内皮機能障害と線維症を引き起こす炎症および線維化促進シグナルを拡散させる。
結論:
- 血小板は、SScにおける免疫血栓症および血栓炎症を調整する。
- 血小板シグナル伝達ネットワークは、リスク層別化および治療の標的を提供する。
- SScにおける疾患修飾性抗血小板介入のエビデンスは、現在限定的である。
関連する概念動画
Formation of the Platelet Plug
10.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.1K
Structure and Function of Platelets
4.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Introduction to Hemostasis
15.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
15.4K
Clot Retraction and Fibrinolysis
9.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.7K


